BridgeBio Pharma, Inc. Cost of Revenue
BridgeBio Pharma, Inc. (BBIO) reported Cost of Revenue of $15.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-10
- BridgeBio Pharma, Inc. cost of revenue for the quarter ending 2026-06-30 was $15.05M, a 311.88% increase year-over-year.
- BridgeBio Pharma, Inc. cost of revenue for the quarter ending 2026-03-31 was $9.94M, a 276.62% increase year-over-year.
- BridgeBio Pharma, Inc. cost of revenue for the quarter ending 2025-12-31 was $8.11M, a 289.01% increase year-over-year.
- BridgeBio Pharma, Inc. cost of revenue for the quarter ending 2025-09-30 was $6.56M, a 997.49% increase year-over-year.
- BridgeBio Pharma, Inc. cost of revenue for fiscal 2025 was $20.96M, a 440.54% increase from fiscal 2024.
- BridgeBio Pharma, Inc. cost of revenue for fiscal 2024 was $3.88M, a 58.54% increase from fiscal 2023.
- BridgeBio Pharma, Inc. cost of revenue for fiscal 2023 was $2.45M, a 28.77% decline from fiscal 2022.
- BridgeBio Pharma, Inc. cost of revenue for fiscal 2022 was $3.43M, a 10.28% increase from fiscal 2021.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.05M 10-Q · filed 2026-08-10 | $24.98M 10-Q · filed 2026-08-10 | $33.09M derived: sum of 3 quarters · filed 2026-08-10 | $39.66M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $9.94M 10-Q · filed 2026-05-07 | $18.05M derived: sum of 2 quarters · filed 2026-05-07 | $24.61M derived: sum of 3 quarters · filed 2026-05-07 | $28.26M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $8.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $14.67M derived: sum of 2 quarters · filed 2026-02-24 | $18.32M derived: sum of 3 quarters · filed 2026-08-10 | $20.96M 10-K · filed 2026-02-24 |
| 2025-09-30 | $6.56M 10-Q · filed 2025-10-29 | $10.22M derived: sum of 2 quarters · filed 2026-08-10 | $12.86M 10-Q · filed 2025-10-29 | $14.94M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $3.65M 10-Q · filed 2026-08-10 | $6.29M 10-Q · filed 2026-08-10 | $8.38M derived: sum of 3 quarters · filed 2026-08-10 | $8.97M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $2.64M 10-Q · filed 2026-05-07 | $4.72M derived: sum of 2 quarters · filed 2026-05-07 | $5.32M derived: sum of 3 quarters · filed 2026-05-07 | $5.92M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.68M derived: sum of 2 quarters · filed 2026-02-24 | $3.28M derived: sum of 3 quarters · filed 2026-02-24 | $3.88M 10-K · filed 2026-02-24 |
| 2024-09-30 | $598.00K 10-Q · filed 2025-10-29 | $1.20M derived: sum of 2 quarters · filed 2025-10-29 | $1.79M 10-Q · filed 2025-10-29 | $2.39M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $598.00K 10-Q · filed 2025-08-05 | $1.20M 10-Q · filed 2025-08-05 | $1.79M derived: sum of 3 quarters · filed 2026-02-24 | $2.39M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $598.00K 10-Q · filed 2025-04-29 | $1.20M derived: sum of 2 quarters · filed 2026-02-24 | $1.79M derived: sum of 3 quarters · filed 2026-02-24 | $2.39M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $598.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.20M derived: sum of 2 quarters · filed 2026-02-24 | $1.79M derived: sum of 3 quarters · filed 2026-02-24 | $2.45M 10-K · filed 2026-02-24 |
| 2023-09-30 | $598.00K 10-Q · filed 2024-11-12 | $1.20M derived: sum of 2 quarters · filed 2024-11-12 | $1.85M 10-Q · filed 2024-11-12 | $2.50M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $599.00K 10-Q · filed 2024-08-01 | $1.25M 10-Q · filed 2024-08-01 | $1.90M derived: sum of 3 quarters · filed 2025-02-20 | $2.64M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $651.00K 10-Q · filed 2024-05-02 | $1.30M derived: sum of 2 quarters · filed 2025-02-20 | $2.04M derived: sum of 3 quarters · filed 2025-02-20 | $2.74M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $647.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $1.39M derived: sum of 2 quarters · filed 2025-02-20 | $2.09M derived: sum of 3 quarters · filed 2025-02-20 | $3.43M 10-K · filed 2025-02-20 |
| 2022-09-30 | $739.00K 10-Q · filed 2023-11-02 | $1.44M derived: sum of 2 quarters · filed 2023-11-02 | $2.79M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $700.00K 10-Q · filed 2023-08-03 | $2.05M 10-Q · filed 2023-08-03 | ||
| 2021-12-31 | $3.11M 10-K · filed 2024-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |